Zydus to buy Nesher Pharmaceuticals

Published: 20-Jun-2011
Finance Pharmaceutical

Will allow Zydus to make and sell generic controlled drugs in the UK


Zydus Pharmaceuticals, a New Jersey, US-based subsidiary of Indian drugmaker Cadila Healthcare, is to buy K-V Pharmaceutical Company’s generics subsidiary Nesher Pharmaceuticals for approximately US$60m in cash. The acquisition will allow Zydus to make and sell generic controlled substances in the US, which otherwise cannot be imported.

The transaction includes Nesher’s existing and future portfolio of generic drugs, certain manufacturing facilities and a research and development centre.

The deal is expected is to close during the second quarter of K-V's 2012 financial year.

KV said the sale is an important element of the company's strategy to become a branded specialist pharmaceutical company focused on women's health.

  • Companies:
  • Zydus Cadila
See more

You may also like

Pharmaceutical

Indian pharma firms develop niche portfolios

Read more
They aim to take advantage of generic growth in the US over the next two years

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. Indian government bans three medicines owing to health risks Decision follows strong stand on suspending marketing of all drugs prohibited for sale in other countries, including the US, UK, EU and Australia
  3. Dickson achieves ISO 14001 certification ISO 14001 certification highlights a companies' long-term efforts to manage its environmental impact
  4. The key role of IVDs in healthcare: challenges to commercialisation and access In simple terms, in vitro diagnostic (IVD) tests are done on samples such as blood or tissue that have been taken from the human body. IVDs can detect diseases, conditions and infections, provide patients with a better understanding of their ailment and how it might be managed and changed with treatment
  5. AstraZeneca to stop production of Pulmicort pMDI Agreements with SkyePharma expected to be terminated

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Pharmaceutical

Indian pharma firms develop niche portfolios

They aim to take advantage of generic growth in the US over the next two years
Pharmaceutical

Indian generic manufacturers aim to enter the Japanese market

The penetration of generic drugs in Japan is a little more than 30% compared with more 80% in the US market
Pharmaceutical

Indian manufacturers set to cash in on US generics market

Indian pharma companies are well positioned to generate strong revenues from the US generics market
Finance

Bayer strengthens pharmaceutical business in India

Signs joint venture agreement with Zydus Pharma
Sustainability

Building strong foundations for a resilient and planet-friendly future

Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security
Sustainability

Dickson achieves ISO 14001 certification

ISO 14001 certification highlights a companies' long-term efforts to manage its environmental impact
Regulatory

The key role of IVDs in healthcare: challenges to commercialisation and access

In simple terms, in vitro diagnostic (IVD) tests are done on samples such as blood or tissue that have been taken from the human body. IVDs can detect diseases, conditions and infections, provide patients with a better understanding of their ailment and how it might be managed and changed with treatment
Subscribe now